Brief: Recursion Announces First Patient Dosed In Phase 2 Clinical Study Of Rec-3964, A Potential First-In-Class, Oral, Non-Antibiotic Small Molecule For Recurrent Clostridioides Difficile Infection

Recursion Pharmaceuticals

22/10/2024 14:40

Oct 22 (Reuters) - Recursion Pharmaceuticals Inc
 RXRX.O :
    * RECURSION ANNOUNCES FIRST PATIENT DOSED IN PHASE 2
CLINICAL
STUDY OF REC-3964, A POTENTIAL FIRST-IN-CLASS, ORAL,
NON-ANTIBIOTIC SMALL MOLECULE FOR RECURRENT CLOSTRIDIOIDES
DIFFICILE INFECTION

Source text for Eikon:  ID:nGNXc6Mnjb 
Further company coverage:  RXRX.O 

 ((Reuters.Briefs@thomsonreuters.com))